Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Sells $282,299.76 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 492 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $573.78, for a total value of $282,299.76. Following the completion of the transaction, the senior vice president now directly owns 4,056 shares in the company, valued at $2,327,251.68. The trade was a 10.82 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Intuitive Surgical Trading Up 1.8 %

NASDAQ:ISRG opened at $568.02 on Thursday. The stock has a market cap of $202.32 billion, a P/E ratio of 88.61, a PEG ratio of 5.85 and a beta of 1.43. The stock has a 50 day simple moving average of $571.70 and a 200 day simple moving average of $530.90. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00.

Institutional Trading of Intuitive Surgical

Several hedge funds have recently added to or reduced their stakes in the company. Bennett Selby Investments LP lifted its holdings in Intuitive Surgical by 3.9% during the 4th quarter. Bennett Selby Investments LP now owns 449 shares of the medical equipment provider’s stock worth $234,000 after purchasing an additional 17 shares during the last quarter. Onefund LLC lifted its holdings in Intuitive Surgical by 1.9% during the 4th quarter. Onefund LLC now owns 947 shares of the medical equipment provider’s stock worth $494,000 after purchasing an additional 18 shares during the last quarter. AlphaCore Capital LLC increased its stake in Intuitive Surgical by 4.2% during the 4th quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider’s stock worth $235,000 after acquiring an additional 18 shares during the period. LVW Advisors LLC increased its stake in Intuitive Surgical by 1.3% during the 4th quarter. LVW Advisors LLC now owns 1,448 shares of the medical equipment provider’s stock worth $756,000 after acquiring an additional 19 shares during the period. Finally, Wesbanco Bank Inc. increased its stake in Intuitive Surgical by 1.6% during the 4th quarter. Wesbanco Bank Inc. now owns 1,216 shares of the medical equipment provider’s stock worth $635,000 after acquiring an additional 19 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several recent analyst reports. Citigroup increased their price target on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Morgan Stanley upgraded Intuitive Surgical from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $522.00 to $650.00 in a report on Monday, December 2nd. Wells Fargo & Company increased their price target on Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. BTIG Research increased their price target on Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Finally, Erste Group Bank upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $613.10.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.